Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY (TRIPLE-CLASS REFRACTORY MM)

NCT05228470 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05228470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05228470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY (TRIPLE-CLASS REFRACTORY MM)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 21, 2021
Completion date
September 11, 2025
Enrollment
39 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bcma, bcma-cd3 bispecific, bispecific, bispecific antibody, elranatamab, magnetismm-8, multiple myeloma, myeloma, pf-06863135, refractory multiple myeloma, relapsed multiple myeloma